1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Neuralgia Global Clinical Trials Review, H2, 2014

Neuralgia Global Clinical Trials Review, H2, 2014

  • July 2014
  • -
  • Global Data
  • -
  • 163 pages

Neuralgia Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, “Neuralgia Global Clinical Trials Review, H2, 2014" provides data on the Neuralgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuralgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuralgia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Neuralgia Global Clinical Trials Review, H2, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Neuralgia 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Neuralgia to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Neuralgia to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Neuralgia 25
Subjects Recruited Over a Period of Time 32
Clinical Trials by Sponsor Type 33
Prominent Sponsors 34
Top Companies Participating in Neuralgia Therapeutics Clinical Trials 35
Prominent Drugs 37
Clinical Trial Profiles 38
Clinical Trial Overview of Top Companies 38
Pfizer Inc. 38
Clinical Trial Overview of Pfizer Inc. 38
AstraZeneca PLC 43
Clinical Trial Overview of AstraZeneca PLC 43
NeurogesX, Inc. 45
Clinical Trial Overview of NeurogesX, Inc. 45
Grunenthal GmbH 46
Clinical Trial Overview of Grunenthal GmbH 46
GlaxoSmithKline plc 47
Clinical Trial Overview of GlaxoSmithKline plc 47
GW Pharmaceuticals plc 48
Clinical Trial Overview of GW Pharmaceuticals plc 48
Merck and Co., Inc. 49
Clinical Trial Overview of Merck and Co., Inc. 49
Spinifex Pharmaceuticals Pty Limited 50
Clinical Trial Overview of Spinifex Pharmaceuticals Pty Limited 50
Endo International plc 51
Clinical Trial Overview of Endo International plc 51
Eli Lilly and Company 52
Clinical Trial Overview of Eli Lilly and Company 52
Clinical Trial Overview of Top Institutes / Government 53
University Hospital of Clermont-Ferrand 53
Clinical Trial Overview of University Hospital of Clermont-Ferrand 53
Lawson Health Research Institute 54
Clinical Trial Overview of Lawson Health Research Institute 54
Stanford University 55
Clinical Trial Overview of Stanford University 55
Rigshospitalet 56
Clinical Trial Overview of Rigshospitalet 56
Danish Pain Research Center 57
Clinical Trial Overview of Danish Pain Research Center 57
Leiden University Medical Center 58
Clinical Trial Overview of Leiden University Medical Center 58
Rambam Health Care Campus 59
Clinical Trial Overview of Rambam Health Care Campus 59
University of Manitoba 60
Clinical Trial Overview of University of Manitoba 60
University of California, San Francisco 61
Clinical Trial Overview of University of California, San Francisco 61
U.S. Department of Veterans Affairs 62
Clinical Trial Overview of U.S. Department of Veterans Affairs 62
Five Key Clinical Profiles 63
Appendix 161
Abbreviations 161
Definitions 161
Research Methodology 162
Secondary Research 162
About GlobalData 163
Contact Us 163
Disclaimer 163
Source 163

List of Tables
Neuralgia Therapeutics, Global, Clinical Trials by Region, 2014* 7
Neuralgia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Neuralgia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Neuralgia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Neuralgia Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Neuralgia Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Neuralgia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Neuralgia Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Neuralgia to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Neuralgia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Neuralgia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Neuralgia to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Neuralgia Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Neuralgia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Neuralgia Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Neuralgia Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Neuralgia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Neuralgia Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Neuralgia Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Neuralgia Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Neuralgia Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Neuralgia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 32
Neuralgia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 33
Neuralgia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 34
Neuralgia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 36
Neuralgia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 37
Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 38
Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 43
Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by NeurogesX, Inc., 2014* 45
Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Grunenthal GmbH, 2014* 46
Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 47
Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by GW Pharmaceuticals plc, 2014* 48
Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 49
Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Spinifex Pharmaceuticals Pty Limited, 2014* 50
Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Endo International plc, 2014* 51
Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 52
Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital of Clermont-Ferrand, 2014* 53
Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Lawson Health Research Institute, 2014* 54
Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 55
Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Rigshospitalet, 2014* 56
Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Danish Pain Research Center, 2014* 57
Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Leiden University Medical Center, 2014* 58
Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Rambam Health Care Campus, 2014* 59
Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Manitoba, 2014* 60
Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 61
Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2014* 62

List of Figures
Neuralgia Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Neuralgia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Neuralgia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Neuralgia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Neuralgia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Neuralgia Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Neuralgia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Neuralgia Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Neuralgia to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Neuralgia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Neuralgia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Neuralgia to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Neuralgia Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Neuralgia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Neuralgia Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Neuralgia Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Neuralgia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Neuralgia Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Neuralgia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 32
Neuralgia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 33
Neuralgia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 34
Neuralgia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 35
Neuralgia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 37
GlobalData Methodology 162

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.